Abstract
In recent decades, the prospect of using a biomarker strategy for early personalized diagnosis of cardiovascular pathologies has been actively explored. The use of new markers appears promising, and the search for an ideal marker is actively ongoing, which will make it possible to understand various mechanisms of cardiovascular diseases. In recent years, scientists have actively focused on studying the role of neuregulin-1 as a laboratory biological marker in cardiac pathology. Neuregulins belong to a superfamily of epidermal growth factors that are synthesized by the vascular endothelium in response to ischemia, adrenergic stimulation, and oxidative stress.
Several studies have shown the potentially important diagnostic and prognostic value of assessing neuregulin-1 as a biological marker. Thus, further scientific and clinical studies will demonstrate the possibility of using this marker as an additional laboratory tool for diagnosing, risk stratifying, and predicting cardiovascular events in patients with cardiovascular pathology. The therapeutic effect of recombinant neuregulin-1 on reducing morbidity and mortality in patients with cardiac disorders require more detailed assessments.